{"artifact":{"id":"experiment-exp-c98631a3-a95e-4621-a68f-9cf145b22b97","artifact_type":"experiment","entity_ids":"[\"P2RX1, P2RX4, P2RX5, P2RX7, P2RY1, P2RY12, PANX1, ADORA2B, NLRP3, F3, ENTPD1, CD38\"]","title":"Leukocyte gene expression analysis in COVID-19 patients","quality_score":0.9,"created_by":"experiment_extractor","provenance_chain":"[]","content_hash":"d9ba93e5efd1f3cea435c7dbf58facac96cf928bc7f92e125fd3498e5ab4b2a5","metadata":{"_origin":{"url":null,"type":"internal","tracked_at":"2026-04-10T14:42:34.607902"},"p_value":null,"protocol":"Raw genomics data from COVID-19 patient samples obtained by microarray from GEO databases, analyzed using bioinformatics and statistical methods","effect_size":null,"sample_size":null,"source_pmid":"35091759","extracted_at":"2026-04-10T07:42:34.604166","_schema_version":1,"experiment_type":"gene_expression","success_criteria":"Significant upregulation of target genes in COVID-19 patients","expected_outcomes":"Upregulation of purinergic receptor genes and ectoenzymes in COVID-19 patients compared to controls","statistical_methods":"bioinformatics and statistical methods"},"created_at":"2026-04-10T14:42:34-07:00","updated_at":"2026-04-10T14:42:34-07:00","version_number":4,"parent_version_id":null,"version_tag":null,"changelog":null,"is_latest":1,"lifecycle_state":"active","superseded_by":null,"deprecated_at":null,"deprecated_reason":null,"dependencies":null,"market_price":0.5,"origin_type":"internal","origin_url":null,"lifecycle_changed_at":"2026-04-10T14:42:34-07:00","citation_count":0,"embed_count":0,"derivation_count":0,"support_count":0,"contradiction_count":0,"total_usage":0.0,"usage_score":0.5,"usage_computed_at":null,"quality_status":"ok","contributors":[],"answers_question_ids":null,"deprecated_reason_detail":null,"deprecated_reason_code":null,"commit_sha":null,"commit_submodule":null,"last_mutated_at":"2026-05-16T14:51:34.657673-07:00","disputed_at":null,"gap_id":null,"mission_id":null,"intrinsic_priority":null,"effective_priority":null,"artifact_id":"917ef726-d316-449e-8ac7-ec83ce424657","artifact_dir":null,"primary_filename":null,"accessory_filenames":null,"folder_layout_version":1,"migrated_to_folder_at":null,"hypothesis_id":null,"authorship":{"kind":"human","contributors":[{"role":"author","actor_ref":"experiment_extractor"}]},"epistemic_tier":"T3_provisional","created_by_agent_id":null},"outgoing_links":[{"target_artifact_id":"paper-35091759","link_type":"derives_from","strength":1.0,"evidence":"Extracted from paper abstract/full text"},{"target_artifact_id":"wiki-genes-cd38","link_type":"related","strength":0.63,"evidence":"Reverse: Gene mention: CD38"},{"target_artifact_id":"wiki-proteins-panx1","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: PANX1"},{"target_artifact_id":"wiki-investment-nlrp3-inflammasome","link_type":"related","strength":0.63,"evidence":"Reverse: Gene mention: NLRP3"},{"target_artifact_id":"wiki-mechanisms-nlrp3-inflammasome-pathway-neurodegeneration","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"},{"target_artifact_id":"wiki-therapeutics-nlrp3-inhibitors","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"},{"target_artifact_id":"wiki-mechanisms-nlrp3-inflammasome-ad-pathway","link_type":"related","strength":0.63,"evidence":"Reverse: Gene mention: NLRP3"},{"target_artifact_id":"wiki-proteins-p2rx7-protein","link_type":"related","strength":0.63,"evidence":"Reverse: Gene mention: P2RX7"},{"target_artifact_id":"wiki-genes-panx1","link_type":"related","strength":0.63,"evidence":"Reverse: Gene mention: PANX1"},{"target_artifact_id":"wiki-mechanisms-nlrp3-inhibitor-early-pd-trial","link_type":"related","strength":0.63,"evidence":"Reverse: Gene mention: NLRP3"},{"target_artifact_id":"wiki-therapeutics-nlrp3-inhibitors-neurodegeneration","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"},{"target_artifact_id":"wiki-ideas-cd38-inhibition-nad-synergy","link_type":"related","strength":0.63,"evidence":"Reverse: Gene mention: CD38"},{"target_artifact_id":"wiki-therapeutics-nlrp3-inflammasome-inhibitors","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"},{"target_artifact_id":"wiki-genes-p2rx1","link_type":"related","strength":0.63,"evidence":"Reverse: Gene mention: P2RX1"},{"target_artifact_id":"wiki-therapeutics-cd38-inhibitor-therapy-neurodegeneration","link_type":"related","strength":0.63,"evidence":"Reverse: Gene mention: CD38"},{"target_artifact_id":"wiki-hypotheses-nlrp3-inflammasome-parkinsons","link_type":"related","strength":0.63,"evidence":"Reverse: Gene mention: NLRP3"},{"target_artifact_id":"wiki-therapeutics-nlrp3-senomorphic-cycling","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"},{"target_artifact_id":"wiki-genes-p2rx4","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: P2RX4"},{"target_artifact_id":"wiki-entities-nlrp3-inflammasome","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"},{"target_artifact_id":"wiki-proteins-adora2b-protein","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: ADORA2B"},{"target_artifact_id":"wiki-genes-p2ry12","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: P2RY12"},{"target_artifact_id":"wiki-genes-p2ry1","link_type":"related","strength":0.63,"evidence":"Reverse: Gene mention: P2RY1"},{"target_artifact_id":"wiki-therapeutics-nlrp3-inhibitors-parkinsons","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"},{"target_artifact_id":"wiki-mechanisms-nlrp3-inflammasome-neurodegeneration","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"},{"target_artifact_id":"wiki-experiments-nlrp3-inflammasome-parkinsons","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"},{"target_artifact_id":"wiki-mechanisms-nlrp3-inflammasome-inhibitors-parkinsons","link_type":"related","strength":0.63,"evidence":"Reverse: Gene mention: NLRP3"},{"target_artifact_id":"wiki-datasets","link_type":"related","strength":0.54,"evidence":"Reverse: Title match: Datasets"},{"target_artifact_id":"wiki-proteins-nlrp3","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"},{"target_artifact_id":"wiki-mechanisms-nlrp3-inflammasome-activation-pathway","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"},{"target_artifact_id":"wiki-genes-p2rx7","link_type":"related","strength":0.63,"evidence":"Reverse: Gene mention: P2RX7"},{"target_artifact_id":"wiki-cell-types-nlrp3-inflammasome-activated-microglia","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"},{"target_artifact_id":"wiki-ideas-nlrp3-senomorphic-cycling-therapy","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"},{"target_artifact_id":"wiki-mechanisms-nlrp3-inflammasome","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"},{"target_artifact_id":"wiki-proteins-nlrp3-protein","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"},{"target_artifact_id":"wiki-mechanisms-covid-19-neurodegeneration","link_type":"related","strength":0.63,"evidence":"Reverse: Gene mention: COVID"},{"target_artifact_id":"wiki-cell-types-nrlp3-activated-microglia","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NLRP3"},{"target_artifact_id":"wiki-genes-p2rx5","link_type":"related","strength":0.63,"evidence":"Reverse: Gene mention: P2RX5"},{"target_artifact_id":"wiki-genes-adora2b","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: ADORA2B"},{"target_artifact_id":"wiki-genes-adora2b","link_type":"mentions","strength":0.5,"evidence":"Entity ADORA2B in experiment"},{"target_artifact_id":"wiki-genes-p2rx1","link_type":"mentions","strength":0.5,"evidence":"Entity P2RX1 in experiment"},{"target_artifact_id":"wiki-genes-p2rx5","link_type":"mentions","strength":0.5,"evidence":"Entity P2RX5 in experiment"},{"target_artifact_id":"wiki-genes-p2rx7","link_type":"mentions","strength":0.5,"evidence":"Entity P2RX7 in experiment"},{"target_artifact_id":"wiki-genes-panx1","link_type":"mentions","strength":0.5,"evidence":"Entity PANX1 in experiment"},{"target_artifact_id":"wiki-proteins-nlrp3","link_type":"mentions","strength":0.5,"evidence":"Entity NLRP3 in experiment"},{"target_artifact_id":"wiki-genes-p2ry1","link_type":"mentions","strength":0.5,"evidence":"Entity P2RY1 in experiment"},{"target_artifact_id":"wiki-genes-p2ry12","link_type":"mentions","strength":0.5,"evidence":"Entity P2RY12 in experiment"},{"target_artifact_id":"wiki-genes-p2rx4","link_type":"mentions","strength":0.5,"evidence":"Entity P2RX4 in experiment"},{"target_artifact_id":"wiki-genes-cd38","link_type":"mentions","strength":0.5,"evidence":"Entity CD38 in experiment"}],"incoming_links":[{"source_artifact_id":"wiki-proteins-panx1","link_type":"mentions","strength":0.8,"evidence":"Gene target: PANX1"},{"source_artifact_id":"wiki-investment-nlrp3-inflammasome","link_type":"mentions","strength":0.7,"evidence":"Gene mention: NLRP3"},{"source_artifact_id":"wiki-mechanisms-nlrp3-inflammasome-pathway-neurodegeneration","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-therapeutics-nlrp3-inhibitors","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-mechanisms-nlrp3-inflammasome-ad-pathway","link_type":"mentions","strength":0.7,"evidence":"Gene mention: NLRP3"},{"source_artifact_id":"wiki-proteins-p2rx7-protein","link_type":"mentions","strength":0.7,"evidence":"Gene mention: P2RX7"},{"source_artifact_id":"wiki-genes-panx1","link_type":"mentions","strength":0.7,"evidence":"Gene mention: PANX1"},{"source_artifact_id":"wiki-mechanisms-nlrp3-inhibitor-early-pd-trial","link_type":"mentions","strength":0.7,"evidence":"Gene mention: NLRP3"},{"source_artifact_id":"wiki-therapeutics-nlrp3-inhibitors-neurodegeneration","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-genes-cd38","link_type":"mentions","strength":0.7,"evidence":"Gene mention: CD38"},{"source_artifact_id":"wiki-ideas-cd38-inhibition-nad-synergy","link_type":"mentions","strength":0.7,"evidence":"Gene mention: CD38"},{"source_artifact_id":"wiki-therapeutics-nlrp3-inflammasome-inhibitors","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-genes-p2rx1","link_type":"mentions","strength":0.7,"evidence":"Gene mention: P2RX1"},{"source_artifact_id":"wiki-therapeutics-cd38-inhibitor-therapy-neurodegeneration","link_type":"mentions","strength":0.7,"evidence":"Gene mention: CD38"},{"source_artifact_id":"wiki-hypotheses-nlrp3-inflammasome-parkinsons","link_type":"mentions","strength":0.7,"evidence":"Gene mention: NLRP3"},{"source_artifact_id":"wiki-therapeutics-nlrp3-senomorphic-cycling","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-genes-p2rx4","link_type":"mentions","strength":0.8,"evidence":"Gene target: P2RX4"},{"source_artifact_id":"wiki-entities-nlrp3-inflammasome","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-proteins-adora2b-protein","link_type":"mentions","strength":0.8,"evidence":"Gene target: ADORA2B"},{"source_artifact_id":"wiki-genes-p2ry12","link_type":"mentions","strength":0.8,"evidence":"Gene target: P2RY12"},{"source_artifact_id":"wiki-genes-p2ry1","link_type":"mentions","strength":0.7,"evidence":"Gene mention: P2RY1"},{"source_artifact_id":"wiki-therapeutics-nlrp3-inhibitors-parkinsons","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-mechanisms-nlrp3-inflammasome-neurodegeneration","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-experiments-nlrp3-inflammasome-parkinsons","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-mechanisms-nlrp3-inflammasome-inhibitors-parkinsons","link_type":"mentions","strength":0.7,"evidence":"Gene mention: NLRP3"},{"source_artifact_id":"wiki-datasets","link_type":"mentions","strength":0.6,"evidence":"Title match: Datasets"},{"source_artifact_id":"wiki-proteins-nlrp3","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-mechanisms-nlrp3-inflammasome-activation-pathway","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-genes-p2rx7","link_type":"mentions","strength":0.7,"evidence":"Gene mention: P2RX7"},{"source_artifact_id":"wiki-cell-types-nlrp3-inflammasome-activated-microglia","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-ideas-nlrp3-senomorphic-cycling-therapy","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-mechanisms-nlrp3-inflammasome","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-proteins-nlrp3-protein","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-mechanisms-covid-19-neurodegeneration","link_type":"mentions","strength":0.7,"evidence":"Gene mention: COVID"},{"source_artifact_id":"wiki-cell-types-nrlp3-activated-microglia","link_type":"mentions","strength":0.8,"evidence":"Gene target: NLRP3"},{"source_artifact_id":"wiki-genes-p2rx5","link_type":"mentions","strength":0.7,"evidence":"Gene mention: P2RX5"},{"source_artifact_id":"wiki-genes-adora2b","link_type":"mentions","strength":0.8,"evidence":"Gene target: ADORA2B"},{"source_artifact_id":"wiki-entities","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 10x in wiki/entities"},{"source_artifact_id":"wiki-experiments","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/experiments"},{"source_artifact_id":"wiki-ideas","link_type":"mentions","strength":0.5,"evidence":"Content: CD38 mentioned 3x in wiki/ideas"},{"source_artifact_id":"wiki-therapeutics-dietary-interventions-parkinsons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-dietary-interventions-parkinsons"},{"source_artifact_id":"wiki-therapeutics-ad-pd-target-comparison-matrix","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-ad-pd-target-comparison-matrix"},{"source_artifact_id":"wiki-therapeutics-nmn-nad-precursor-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: CD38 mentioned 4x in wiki/therapeutics-nmn-nad-precursor-parkinsons"},{"source_artifact_id":"wiki-therapeutics-csf1r-inhibitors-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-csf1r-inhibitors-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-tgf-beta-modulation-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-tgf-beta-modulation-therapy"},{"source_artifact_id":"wiki-therapeutics-p2x7-receptor-antagonists-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 19x in wiki/therapeutics-p2x7-receptor-antagonists-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-nadph-oxidase-inhibitors","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-nadph-oxidase-inhibitors"},{"source_artifact_id":"wiki-therapeutics-ketogenic-diet-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-ketogenic-diet-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-4r-tauopathy-targets","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 6x in wiki/therapeutics-4r-tauopathy-targets"},{"source_artifact_id":"wiki-therapeutics-autophagy-inducers-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-autophagy-inducers-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-connexin-pannexin-hemichannel-modulation","link_type":"mentions","strength":0.5,"evidence":"Content: PANX1 mentioned 6x in wiki/therapeutics-connexin-pannexin-hemichannel-modulation"},{"source_artifact_id":"wiki-therapeutics-hyperbaric-oxygen-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/therapeutics-hyperbaric-oxygen-therapy"},{"source_artifact_id":"wiki-therapeutics-kamuvudine-9-alzheimers","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 8x in wiki/therapeutics-kamuvudine-9-alzheimers"},{"source_artifact_id":"wiki-therapeutics-alpha-synuclein-targeting-therapies","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-alpha-synuclein-targeting-therapies"},{"source_artifact_id":"wiki-therapeutics-synaptic-plasticity-therapeutics-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-synaptic-plasticity-therapeutics-pd"},{"source_artifact_id":"wiki-therapeutics-galectin-3-modulation-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-galectin-3-modulation-therapy"},{"source_artifact_id":"wiki-therapeutics-supplements-guide-cbs-psp","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-supplements-guide-cbs-psp"},{"source_artifact_id":"wiki-therapeutics-pannexin-hemichannel-modulation-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: PANX1 mentioned 41x in wiki/therapeutics-pannexin-hemichannel-modulation-therapy"},{"source_artifact_id":"wiki-therapeutics-section-99-purinergic-signaling","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 7x in wiki/therapeutics-section-99-purinergic-signaling"},{"source_artifact_id":"wiki-therapeutics-section-147-neuroimmune-glial-crosstalk-cbs-psp","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-section-147-neuroimmune-glial-crosstalk-cbs-psp"},{"source_artifact_id":"wiki-therapeutics-alpha-lipoic-acid-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-alpha-lipoic-acid-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-mtor-inhibitor-therapy-parkinsons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-mtor-inhibitor-therapy-parkinsons"},{"source_artifact_id":"wiki-therapeutics-carbon-monoxide-therapy-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-carbon-monoxide-therapy-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-senolytic-therapies-parkinsons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-senolytic-therapies-parkinsons"},{"source_artifact_id":"wiki-therapeutics-microglia-modulation-therapies","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 13x in wiki/therapeutics-microglia-modulation-therapies"},{"source_artifact_id":"wiki-therapeutics-immune-drug-repurposing-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 10x in wiki/therapeutics-immune-drug-repurposing-parkinsons"},{"source_artifact_id":"wiki-therapeutics-urolithin-a-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/therapeutics-urolithin-a-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-pyroptosis-inhibition-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 33x in wiki/therapeutics-pyroptosis-inhibition-therapy"},{"source_artifact_id":"wiki-therapeutics-cbs-psp-daily-action-plan","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 10x in wiki/therapeutics-cbs-psp-daily-action-plan"},{"source_artifact_id":"wiki-therapeutics-nad-boosters-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: CD38 mentioned 5x in wiki/therapeutics-nad-boosters-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-section-132-systems-immunology-network-pharmacology-cbs-psp","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/therapeutics-section-132-systems-immunology-network-pharmacology-cbs-psp"},{"source_artifact_id":"wiki-therapeutics-section-118-neuroinflammation-imaging-advanced-cbs-psp","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-section-118-neuroinflammation-imaging-advanced-cbs-psp"},{"source_artifact_id":"wiki-therapeutics-anti-inflammatory-therapy-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 6x in wiki/therapeutics-anti-inflammatory-therapy-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-microglia-modulation-therapy-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 8x in wiki/therapeutics-microglia-modulation-therapy-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-microglial-priming-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-microglial-priming-therapy"},{"source_artifact_id":"wiki-therapeutics-intermittent-fasting-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-intermittent-fasting-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-sulforaphane-nrf2-neuroprotection","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-sulforaphane-nrf2-neuroprotection"},{"source_artifact_id":"wiki-therapeutics-p2x7-receptor-modulation-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 17x in wiki/therapeutics-p2x7-receptor-modulation-therapy"},{"source_artifact_id":"wiki-therapeutics-cbs-psp-nutritional-therapy","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-cbs-psp-nutritional-therapy"},{"source_artifact_id":"wiki-therapeutics-multi-target-pharmacotherapy-cbs-psp","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-multi-target-pharmacotherapy-cbs-psp"},{"source_artifact_id":"wiki-therapeutics-spermidine-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-spermidine-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-cgrp-receptor-modulators-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-cgrp-receptor-modulators-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-neuroprotection","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 8x in wiki/therapeutics-neuroprotection"},{"source_artifact_id":"wiki-therapeutics-exosome-based-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-exosome-based-therapeutics"},{"source_artifact_id":"wiki-therapeutics-nad-precursors-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: CD38 mentioned 4x in wiki/therapeutics-nad-precursors-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-urolithin-a-mitophagy","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-urolithin-a-mitophagy"},{"source_artifact_id":"wiki-therapeutics-s100-protein-modulator-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 10x in wiki/therapeutics-s100-protein-modulator-therapy"},{"source_artifact_id":"wiki-therapeutics-treatment-pipeline","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-treatment-pipeline"},{"source_artifact_id":"wiki-therapeutics-ketone-body-therapy-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-ketone-body-therapy-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-nutritional-therapy-cbs-psp","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-nutritional-therapy-cbs-psp"},{"source_artifact_id":"wiki-therapeutics-mitochondrial-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-mitochondrial-therapeutics"},{"source_artifact_id":"wiki-therapeutics-metformin-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-metformin-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-neuroinflammation-modulation-therapies","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 11x in wiki/therapeutics-neuroinflammation-modulation-therapies"},{"source_artifact_id":"wiki-therapeutics-sirtuin-modulators-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: CD38 mentioned 3x in wiki/therapeutics-sirtuin-modulators-parkinsons"},{"source_artifact_id":"wiki-therapeutics-sglt2-inhibitors-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/therapeutics-sglt2-inhibitors-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-parp-inhibitor-therapy","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-parp-inhibitor-therapy"},{"source_artifact_id":"wiki-therapeutics-cgas-sting-inhibitor-therapy","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-cgas-sting-inhibitor-therapy"},{"source_artifact_id":"wiki-therapeutics-galectin-3-inhibitor-therapy","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-galectin-3-inhibitor-therapy"},{"source_artifact_id":"wiki-therapeutics-rage-modulator-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-rage-modulator-therapy"},{"source_artifact_id":"wiki-therapeutics-irisin-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-irisin-therapy"},{"source_artifact_id":"wiki-therapeutics-neurodegeneration-therapeutic-target-comparison-matrix","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/therapeutics-neurodegeneration-therapeutic-target-comparison-matrix"},{"source_artifact_id":"wiki-therapeutics-dpp-4-inhibitor-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-dpp-4-inhibitor-therapy"},{"source_artifact_id":"wiki-therapeutics-glp-1-receptor-agonists-parkinsons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-glp-1-receptor-agonists-parkinsons"},{"source_artifact_id":"wiki-therapeutics-cd47-sirp-alpha-immune-checkpoint-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 9x in wiki/therapeutics-cd47-sirp-alpha-immune-checkpoint-therapy"},{"source_artifact_id":"wiki-therapeutics-creatine-neuroprotection","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-creatine-neuroprotection"},{"source_artifact_id":"wiki-therapeutics-nicotinamide-riboside","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-nicotinamide-riboside"},{"source_artifact_id":"wiki-therapeutics-vitamin-d-therapy-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/therapeutics-vitamin-d-therapy-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-corticobasal-degeneration-treatment","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-corticobasal-degeneration-treatment"},{"source_artifact_id":"wiki-therapeutics-cuatsm","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-cuatsm"},{"source_artifact_id":"wiki-therapeutics-melatonin-tauopathy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/therapeutics-melatonin-tauopathy"},{"source_artifact_id":"wiki-therapeutics-aim2-inflammasome-modulator-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 8x in wiki/therapeutics-aim2-inflammasome-modulator-therapy"},{"source_artifact_id":"wiki-therapeutics-section-186-bioenergetics-mitochondrial-coupling-cbs-psp","link_type":"mentions","strength":0.5,"evidence":"Content: CD38 mentioned 6x in wiki/therapeutics-section-186-bioenergetics-mitochondrial-coupling-cbs-psp"},{"source_artifact_id":"wiki-therapeutics-h2s-releasing-compounds-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-h2s-releasing-compounds-parkinsons"},{"source_artifact_id":"wiki-therapeutics-neuroinflammation-targeting-therapies","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 24x in wiki/therapeutics-neuroinflammation-targeting-therapies"},{"source_artifact_id":"wiki-entities-apoptosis","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/entities-apoptosis"},{"source_artifact_id":"wiki-therapeutics-tudca-udca-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/therapeutics-tudca-udca-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-omega-3-fatty-acids-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/therapeutics-omega-3-fatty-acids-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-section-201-mitochondrial-biogenesis-pgc1alpha-cbs-psp","link_type":"mentions","strength":0.5,"evidence":"Content: CD38 mentioned 3x in wiki/therapeutics-section-201-mitochondrial-biogenesis-pgc1alpha-cbs-psp"},{"source_artifact_id":"wiki-therapeutics-specialized-pro-resolving-mediator-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/therapeutics-specialized-pro-resolving-mediator-therapy"},{"source_artifact_id":"wiki-therapeutics-csf1r-inhibitors-parkinsons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-csf1r-inhibitors-parkinsons"},{"source_artifact_id":"wiki-therapeutics-chemokine-receptor-modulation-parkinsons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-chemokine-receptor-modulation-parkinsons"},{"source_artifact_id":"wiki-therapeutics-ibudilast","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/therapeutics-ibudilast"},{"source_artifact_id":"wiki-therapeutics-dapansutrile-parkinsons-disease","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 63x in wiki/therapeutics-dapansutrile-parkinsons-disease"},{"source_artifact_id":"wiki-therapeutics-cue1-device-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-cue1-device-pd"},{"source_artifact_id":"wiki-therapeutics-specialized-pro-resolving-mediator-therapy-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/therapeutics-specialized-pro-resolving-mediator-therapy-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-cd39-activators-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: ENTPD1 mentioned 6x in wiki/therapeutics-cd39-activators-neurodegeneration"},{"source_artifact_id":"wiki-ideas-payload-aim2-inflammasome-modulation-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 8x in wiki/ideas-payload-aim2-inflammasome-modulation-therapy"},{"source_artifact_id":"wiki-therapeutics-molecular-hydrogen-therapy-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/therapeutics-molecular-hydrogen-therapy-parkinsons"},{"source_artifact_id":"wiki-therapeutics-section-103-sirtuin-nad-cbs-psp","link_type":"mentions","strength":0.5,"evidence":"Content: CD38 mentioned 6x in wiki/therapeutics-section-103-sirtuin-nad-cbs-psp"},{"source_artifact_id":"wiki-therapeutics-syk-kinase-inhibitor-therapy","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-syk-kinase-inhibitor-therapy"},{"source_artifact_id":"wiki-therapeutics-omega-3-fatty-acids-parkinsons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-omega-3-fatty-acids-parkinsons"},{"source_artifact_id":"wiki-therapeutics-calorie-restriction-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-calorie-restriction-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-pyroptosis-modulation-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 17x in wiki/therapeutics-pyroptosis-modulation-therapy"},{"source_artifact_id":"wiki-therapeutics-minocycline-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 6x in wiki/therapeutics-minocycline-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-anti-tau-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-anti-tau-therapeutics"},{"source_artifact_id":"wiki-therapeutics-p2x7-receptor-antagonists-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/therapeutics-p2x7-receptor-antagonists-parkinsons"},{"source_artifact_id":"wiki-therapeutics-microglial-modulation-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 10x in wiki/therapeutics-microglial-modulation-therapy"},{"source_artifact_id":"wiki-therapeutics-gut-microbiome-therapy-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 6x in wiki/therapeutics-gut-microbiome-therapy-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-endosomal-lysosomal-trafficking-cbs-psp","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/therapeutics-endosomal-lysosomal-trafficking-cbs-psp"},{"source_artifact_id":"wiki-therapeutics-section-147-neuroimmune-interface-glial-crosstalk-cbs-psp","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 8x in wiki/therapeutics-section-147-neuroimmune-interface-glial-crosstalk-cbs-psp"},{"source_artifact_id":"wiki-therapeutics-adenosine-a2a-receptor-antagonists-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-adenosine-a2a-receptor-antagonists-pd"},{"source_artifact_id":"wiki-therapeutics-sodium-oligomannate-gv971","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/therapeutics-sodium-oligomannate-gv971"},{"source_artifact_id":"wiki-clinical-trials-mk-1167-merck-phase-2-ad-nct06721156","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/clinical-trials-mk-1167-merck-phase-2-ad-nct06721156"},{"source_artifact_id":"wiki-clinical-trials-cbd-ad-prevention-nct05822362","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/clinical-trials-cbd-ad-prevention-nct05822362"},{"source_artifact_id":"wiki-clinical-trials-ct1-dap001-ips-dopaminergic-progenitors-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-ct1-dap001-ips-dopaminergic-progenitors-pd"},{"source_artifact_id":"wiki-clinical-trials-tbu006-parkinson-phase-2a-nct06773962","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/clinical-trials-tbu006-parkinson-phase-2a-nct06773962"},{"source_artifact_id":"wiki-clinical-trials-nct05266417-nose-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-nct05266417-nose-pd"},{"source_artifact_id":"wiki-clinical-trials-commets-semaglutide-mci-nct06072963","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/clinical-trials-commets-semaglutide-mci-nct06072963"},{"source_artifact_id":"wiki-clinical-trials-apocynin-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-apocynin-pd"},{"source_artifact_id":"wiki-clinical-trials-move-brain-pd-nct07299279","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/clinical-trials-move-brain-pd-nct07299279"},{"source_artifact_id":"wiki-clinical-trials-nct06365190-rtms-pd","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/clinical-trials-nct06365190-rtms-pd"},{"source_artifact_id":"wiki-clinical-trials-nct06954662-amino-acid-supplement-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-nct06954662-amino-acid-supplement-pd"},{"source_artifact_id":"wiki-clinical-trials-ab-1005-gdnf-gene-therapy-regenerate-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-ab-1005-gdnf-gene-therapy-regenerate-pd"},{"source_artifact_id":"wiki-clinical-trials-retigabine-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-retigabine-pd"},{"source_artifact_id":"wiki-clinical-trials-pexidartinib-plx3397-csf1r-parkinsons-nct04888966","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/clinical-trials-pexidartinib-plx3397-csf1r-parkinsons-nct04888966"},{"source_artifact_id":"wiki-clinical-trials-nct07308418-vibrotactile-stimulation-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-nct07308418-vibrotactile-stimulation-pd"},{"source_artifact_id":"wiki-clinical-trials-intranasal-insulin-glutathione-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-intranasal-insulin-glutathione-pd"},{"source_artifact_id":"wiki-clinical-trials-biib122-luma-lrrk2-inhibitor-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-biib122-luma-lrrk2-inhibitor-pd"},{"source_artifact_id":"wiki-clinical-trials-nct06687837-autologous-dopaminergic-neurons-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-nct06687837-autologous-dopaminergic-neurons-pd"},{"source_artifact_id":"wiki-clinical-trials-nct06821230-dyadic-mindfulness-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-nct06821230-dyadic-mindfulness-pd"},{"source_artifact_id":"wiki-clinical-trials-xenon-gas-inhalation-neuroinflammation-nct06945614","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 6x in wiki/clinical-trials-xenon-gas-inhalation-neuroinflammation-nct06945614"},{"source_artifact_id":"wiki-clinical-trials-uab-tspo-pet-neuroinflammation-pd-nct03457493","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/clinical-trials-uab-tspo-pet-neuroinflammation-pd-nct03457493"},{"source_artifact_id":"wiki-clinical-trials-metformin-add-on-levodopa-pd-nct07055958","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-metformin-add-on-levodopa-pd-nct07055958"},{"source_artifact_id":"wiki-clinical-trials-valacyclovir-hsv1-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-valacyclovir-hsv1-pd"},{"source_artifact_id":"wiki-clinical-trials-nct07094516-novartis-alzheimers-phase2","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/clinical-trials-nct07094516-novartis-alzheimers-phase2"},{"source_artifact_id":"wiki-clinical-trials-mr-guided-focused-ultrasound-gcase-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-mr-guided-focused-ultrasound-gcase-pd"},{"source_artifact_id":"wiki-clinical-trials-pde4-inhibitor-pd","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/clinical-trials-pde4-inhibitor-pd"},{"source_artifact_id":"wiki-clinical-trials-ne3107-bezisterim-early-parkinsons-nct06757010","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-ne3107-bezisterim-early-parkinsons-nct06757010"},{"source_artifact_id":"wiki-clinical-trials-tb006-parkinson","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/clinical-trials-tb006-parkinson"},{"source_artifact_id":"wiki-clinical-trials-nouvneu001-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-nouvneu001-pd"},{"source_artifact_id":"wiki-clinical-trials-vibrotactile-coordinated-reset-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-vibrotactile-coordinated-reset-pd"},{"source_artifact_id":"wiki-clinical-trials-dapansutrile-pd-nct07157735","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 37x in wiki/clinical-trials-dapansutrile-pd-nct07157735"},{"source_artifact_id":"wiki-investment-peptide-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/investment-peptide-therapeutics"},{"source_artifact_id":"wiki-clinical-trials-dimethyl-fumarate-nrf2-ad-nct06850597","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-dimethyl-fumarate-nrf2-ad-nct06850597"},{"source_artifact_id":"wiki-clinical-trials-nadapt-study-nad-replenishment-parkinsonism-nct06162013","link_type":"mentions","strength":0.5,"evidence":"Content: CD38 mentioned 4x in wiki/clinical-trials-nadapt-study-nad-replenishment-parkinsonism-nct06162013"},{"source_artifact_id":"wiki-clinical-trials-bacillus-subtilis-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/clinical-trials-bacillus-subtilis-pd"},{"source_artifact_id":"wiki-clinical-trials-purinergic-receptor-trials-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/clinical-trials-purinergic-receptor-trials-parkinsons"},{"source_artifact_id":"wiki-hypotheses-post-acute-viral-reservoir-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/hypotheses-post-acute-viral-reservoir-parkinsons"},{"source_artifact_id":"wiki-hypotheses-tryptophan-kynurenine-neurotoxicity-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/hypotheses-tryptophan-kynurenine-neurotoxicity-parkinsons"},{"source_artifact_id":"wiki-hypotheses-stress-granule-dysfunction-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/hypotheses-stress-granule-dysfunction-parkinsons"},{"source_artifact_id":"wiki-hypotheses-pathologic-synergy-occurring-amygdala-betwe","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 6x in wiki/hypotheses-pathologic-synergy-occurring-amygdala-betwe"},{"source_artifact_id":"wiki-hypotheses-cgas-sting-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 12x in wiki/hypotheses-cgas-sting-parkinsons"},{"source_artifact_id":"wiki-hypotheses-gap-junction-dysfunction-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: PANX1 mentioned 13x in wiki/hypotheses-gap-junction-dysfunction-parkinsons"},{"source_artifact_id":"wiki-hypotheses-ferroptosis-parkinsons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/hypotheses-ferroptosis-parkinsons"},{"source_artifact_id":"wiki-hypotheses-purinergic-signaling-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 10x in wiki/hypotheses-purinergic-signaling-parkinsons"},{"source_artifact_id":"wiki-datasets-amp-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/datasets-amp-pd"},{"source_artifact_id":"wiki-ideas-cns-nlrp3-inflammasome-inhibitor","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 21x in wiki/ideas-cns-nlrp3-inflammasome-inhibitor"},{"source_artifact_id":"wiki-ideas-cgas-sting-pathway-inhibitor","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/ideas-cgas-sting-pathway-inhibitor"},{"source_artifact_id":"wiki-ideas-payload-gasdermin-inhibition-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 16x in wiki/ideas-payload-gasdermin-inhibition-therapy"},{"source_artifact_id":"wiki-ideas-payload-trem1-trem2-balanced-microglial-modulation-therapy","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/ideas-payload-trem1-trem2-balanced-microglial-modulation-therapy"},{"source_artifact_id":"wiki-ideas-combo-nlrp3-cd47-immune-reprogramming","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 28x in wiki/ideas-combo-nlrp3-cd47-immune-reprogramming"},{"source_artifact_id":"wiki-ideas-combination-logic-ideas","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: CD38 mentioned 2x in wiki/ideas-combination-logic-ideas"},{"source_artifact_id":"wiki-ideas-novel-therapy-index","link_type":"mentions","strength":0.5,"evidence":"Content: CD38 mentioned 5x in wiki/ideas-novel-therapy-index"},{"source_artifact_id":"wiki-ideas-lrrk2-kinase-modulation-prevention","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/ideas-lrrk2-kinase-modulation-prevention"},{"source_artifact_id":"wiki-ideas-gpnmb-lipid-laden-microglia","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/ideas-gpnmb-lipid-laden-microglia"},{"source_artifact_id":"wiki-ideas-payload-connexin-hemichannel-blockade-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: PANX1 mentioned 8x in wiki/ideas-payload-connexin-hemichannel-blockade-therapy"},{"source_artifact_id":"wiki-ideas-multi-target-synergistic-combination-therapy-framework","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/ideas-multi-target-synergistic-combination-therapy-framework"},{"source_artifact_id":"wiki-ideas-payload-nfkb-pathway-inhibition-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/ideas-payload-nfkb-pathway-inhibition-neurodegeneration"},{"source_artifact_id":"wiki-ideas-glial-therapeutics-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 8x in wiki/ideas-glial-therapeutics-neurodegeneration"},{"source_artifact_id":"wiki-ideas-payload-irak4-kinase-modulation-therapy","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/ideas-payload-irak4-kinase-modulation-therapy"},{"source_artifact_id":"wiki-ideas-combo-sirt1-nad-epigenetic-metabolic","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: CD38 mentioned 2x in wiki/ideas-combo-sirt1-nad-epigenetic-metabolic"},{"source_artifact_id":"wiki-ideas-yap-taz-mechanoactivation-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/ideas-yap-taz-mechanoactivation-therapy"},{"source_artifact_id":"wiki-ideas-payload-ipsc-microglia-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/ideas-payload-ipsc-microglia-therapy"},{"source_artifact_id":"wiki-ideas-payload-ufm1ylation-proteostasis-restoration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/ideas-payload-ufm1ylation-proteostasis-restoration"},{"source_artifact_id":"wiki-ideas-payload-anti-herpetic-viral-therapy-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 7x in wiki/ideas-payload-anti-herpetic-viral-therapy-neurodegeneration"},{"source_artifact_id":"wiki-ideas-astrocytic-mitochondrial-transfer-metabolic-copacking","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: CD38 mentioned 2x in wiki/ideas-astrocytic-mitochondrial-transfer-metabolic-copacking"},{"source_artifact_id":"wiki-ideas-mitochondrial-nad-redox-swing","link_type":"mentions","strength":0.5,"evidence":"Content: CD38 mentioned 3x in wiki/ideas-mitochondrial-nad-redox-swing"},{"source_artifact_id":"wiki-ideas-biomarker-ykl40-antiinflammatory-cycling","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/ideas-biomarker-ykl40-antiinflammatory-cycling"},{"source_artifact_id":"wiki-investment-microbiome-based-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/investment-microbiome-based-therapeutics"},{"source_artifact_id":"wiki-investment-senolytic-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/investment-senolytic-therapeutics"},{"source_artifact_id":"wiki-investment-er-stress-upr-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/investment-er-stress-upr-therapeutics"},{"source_artifact_id":"wiki-investment-adult-neurogenesis-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/investment-adult-neurogenesis-therapeutics"},{"source_artifact_id":"wiki-investment-4r-tauopathy-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/investment-4r-tauopathy-therapeutics"},{"source_artifact_id":"wiki-investment-protein-aggregation-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/investment-protein-aggregation-therapeutics"},{"source_artifact_id":"wiki-investment-complement-system-therapeutics-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/investment-complement-system-therapeutics-neurodegeneration"},{"source_artifact_id":"wiki-investment-pyroptosis-inhibitors-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 19x in wiki/investment-pyroptosis-inhibitors-neurodegeneration"},{"source_artifact_id":"wiki-investment-mitochondrial-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/investment-mitochondrial-therapeutics"},{"source_artifact_id":"wiki-investment-heat-shock-protein-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/investment-heat-shock-protein-therapeutics"},{"source_artifact_id":"wiki-investment-glp-1-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/investment-glp-1-therapeutics"},{"source_artifact_id":"wiki-investment-neuroinflammation","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 12x in wiki/investment-neuroinflammation"},{"source_artifact_id":"wiki-investment-rna-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/investment-rna-therapeutics"},{"source_artifact_id":"wiki-investment-anti-tau-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/investment-anti-tau-therapeutics"},{"source_artifact_id":"wiki-investment-amyloid-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/investment-amyloid-therapeutics"},{"source_artifact_id":"wiki-investment-neuroinflammation-therapeutics","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 8x in wiki/investment-neuroinflammation-therapeutics"},{"source_artifact_id":"wiki-investment-lysosomal-dysfunction-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/investment-lysosomal-dysfunction-therapeutics"},{"source_artifact_id":"wiki-cell-types-globus-pallidus-internus-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/cell-types-globus-pallidus-internus-pd"},{"source_artifact_id":"wiki-cell-types-microglia","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 8x in wiki/cell-types-microglia"},{"source_artifact_id":"wiki-cell-types-iron-laden-microglia","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/cell-types-iron-laden-microglia"},{"source_artifact_id":"wiki-cell-types-nigrostriatal-dopamine-terminals-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/cell-types-nigrostriatal-dopamine-terminals-pd"},{"source_artifact_id":"wiki-cell-types-adenosine-a2b-receptor-neurons-v2","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: ADORA2B mentioned 2x in wiki/cell-types-adenosine-a2b-receptor-neurons-v2"},{"source_artifact_id":"wiki-cell-types-substantia-nigra-neurons-progressive-supranuclear-palsy","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/cell-types-substantia-nigra-neurons-progressive-supranuclear-palsy"},{"source_artifact_id":"wiki-cell-types-adenosine-a2b-receptor-neurons","link_type":"mentions","strength":0.5,"evidence":"Content: ADORA2B mentioned 6x in wiki/cell-types-adenosine-a2b-receptor-neurons"},{"source_artifact_id":"wiki-cell-types-supraoptic-nucleus","link_type":"mentions","strength":0.5,"evidence":"Content: CD38 mentioned 3x in wiki/cell-types-supraoptic-nucleus"},{"source_artifact_id":"wiki-cell-types-microglia-primed","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/cell-types-microglia-primed"},{"source_artifact_id":"wiki-cell-types-mitochondrial-dysfunction-dopaminergic","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/cell-types-mitochondrial-dysfunction-dopaminergic"},{"source_artifact_id":"wiki-cell-types-melanocytes-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/cell-types-melanocytes-pd"},{"source_artifact_id":"wiki-cell-types-reactive-astrocytes-a2","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 13x in wiki/cell-types-reactive-astrocytes-a2"},{"source_artifact_id":"wiki-cell-types-snc-dopamine-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/cell-types-snc-dopamine-pd"},{"source_artifact_id":"wiki-cell-types-amyloid-beta-exposed","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/cell-types-amyloid-beta-exposed"},{"source_artifact_id":"wiki-cell-types-p2x3-receptor-neurons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/cell-types-p2x3-receptor-neurons"},{"source_artifact_id":"wiki-cell-types-amyloid-beta-cortical-neurons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/cell-types-amyloid-beta-cortical-neurons"},{"source_artifact_id":"wiki-cell-types-microglia-in-neuroinflammation","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 9x in wiki/cell-types-microglia-in-neuroinflammation"},{"source_artifact_id":"wiki-cell-types-necroptotic-neurons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/cell-types-necroptotic-neurons"},{"source_artifact_id":"wiki-cell-types-dopaminergic-vta-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/cell-types-dopaminergic-vta-pd"},{"source_artifact_id":"wiki-cell-types-dorsal-raphe-serotonergic-neurons-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/cell-types-dorsal-raphe-serotonergic-neurons-pd"},{"source_artifact_id":"wiki-cell-types-nigral-microglia-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 6x in wiki/cell-types-nigral-microglia-parkinsons"},{"source_artifact_id":"wiki-cell-types-vulnerable-dopaminergic-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/cell-types-vulnerable-dopaminergic-pd"},{"source_artifact_id":"wiki-cell-types-p2x7-receptor-neurons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 10x in wiki/cell-types-p2x7-receptor-neurons"},{"source_artifact_id":"wiki-cell-types-crf-corticoliberin-neurons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/cell-types-crf-corticoliberin-neurons"},{"source_artifact_id":"wiki-cell-types-centromedian-thalamic-nucleus","link_type":"mentions","strength":0.5,"evidence":"Content: P2RX7 mentioned 3x in wiki/cell-types-centromedian-thalamic-nucleus"},{"source_artifact_id":"wiki-cell-types-amyloid-beta-exposed-neurons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/cell-types-amyloid-beta-exposed-neurons"},{"source_artifact_id":"wiki-cell-types-apoe4-homozygous-astrocytes","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/cell-types-apoe4-homozygous-astrocytes"},{"source_artifact_id":"wiki-cell-types-neuroinflammation-microglia","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 9x in wiki/cell-types-neuroinflammation-microglia"},{"source_artifact_id":"wiki-cell-types-hypothalamic-supraoptic-oxytocin","link_type":"mentions","strength":0.5,"evidence":"Content: CD38 mentioned 3x in wiki/cell-types-hypothalamic-supraoptic-oxytocin"},{"source_artifact_id":"wiki-cell-types-oxytocin-neurons","link_type":"mentions","strength":0.5,"evidence":"Content: CD38 mentioned 3x in wiki/cell-types-oxytocin-neurons"},{"source_artifact_id":"wiki-cell-types-hypothalamic-supraoptic-vasopressin","link_type":"mentions","strength":0.5,"evidence":"Content: CD38 mentioned 3x in wiki/cell-types-hypothalamic-supraoptic-vasopressin"},{"source_artifact_id":"wiki-mechanisms-neuroinflammation-alzheimers","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 10x in wiki/mechanisms-neuroinflammation-alzheimers"},{"source_artifact_id":"wiki-mechanisms-cross-disease-neuroinflammation-mechanisms","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 10x in wiki/mechanisms-cross-disease-neuroinflammation-mechanisms"},{"source_artifact_id":"wiki-mechanisms-neuroinflammation-pd","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 20x in wiki/mechanisms-neuroinflammation-pd"},{"source_artifact_id":"wiki-mechanisms-neuroimmune-dysfunction-ftd","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 8x in wiki/mechanisms-neuroimmune-dysfunction-ftd"},{"source_artifact_id":"wiki-mechanisms-neuroinflammation-pd-dementia-with-lewy-bodies","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-neuroinflammation-pd-dementia-with-lewy-bodies"},{"source_artifact_id":"wiki-mechanisms-ceramide-signaling-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-ceramide-signaling-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-complement-system-activation-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-complement-system-activation-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-pd-cure-roadmap","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-pd-cure-roadmap"},{"source_artifact_id":"wiki-mechanisms-investment-signal-synthesis","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-investment-signal-synthesis"},{"source_artifact_id":"wiki-mechanisms-cbs-psp-panxoneopathy-membrane-biology","link_type":"mentions","strength":0.5,"evidence":"Content: PANX1 mentioned 26x in wiki/mechanisms-cbs-psp-panxoneopathy-membrane-biology"},{"source_artifact_id":"wiki-mechanisms-hmgb1-signaling-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-hmgb1-signaling-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-synaptic-dysfunction-hypothesis","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-synaptic-dysfunction-hypothesis"},{"source_artifact_id":"wiki-mechanisms-hypoxia-response","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-hypoxia-response"},{"source_artifact_id":"wiki-mechanisms-amyloid-beta-cellular-uptake","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-amyloid-beta-cellular-uptake"},{"source_artifact_id":"wiki-mechanisms-nf-kb-signaling-neuroinflammation","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 6x in wiki/mechanisms-nf-kb-signaling-neuroinflammation"},{"source_artifact_id":"wiki-mechanisms-nfkb-signaling-pathway","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-nfkb-signaling-pathway"},{"source_artifact_id":"wiki-mechanisms-neuroimmune-checkpoint-metal-oxidative-convergence-synthesis","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 11x in wiki/mechanisms-neuroimmune-checkpoint-metal-oxidative-convergence-synthesis"},{"source_artifact_id":"wiki-mechanisms-tlr-signaling-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 9x in wiki/mechanisms-tlr-signaling-parkinsons"},{"source_artifact_id":"wiki-mechanisms-ginsenosides-neuroprotection-parkinsons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-ginsenosides-neuroprotection-parkinsons"},{"source_artifact_id":"wiki-mechanisms-advanced-glycation-end-products","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-advanced-glycation-end-products"},{"source_artifact_id":"wiki-mechanisms-mtor-autophagy-lysosome-pathway","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-mtor-autophagy-lysosome-pathway"},{"source_artifact_id":"wiki-mechanisms-tau-kinase-signaling-cascade","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-tau-kinase-signaling-cascade"},{"source_artifact_id":"wiki-mechanisms-gene-mechanism-therapy-causal-chains","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-gene-mechanism-therapy-causal-chains"},{"source_artifact_id":"wiki-mechanisms-pyroptosis","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 12x in wiki/mechanisms-pyroptosis"},{"source_artifact_id":"wiki-mechanisms-convergent-molecular-mechanisms","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-convergent-molecular-mechanisms"},{"source_artifact_id":"wiki-mechanisms-microglia-neuron-metabolic-crosstalk","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-microglia-neuron-metabolic-crosstalk"},{"source_artifact_id":"wiki-mechanisms-protein-o-glcna-cylation-pathway","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-protein-o-glcna-cylation-pathway"},{"source_artifact_id":"wiki-mechanisms-g-proteins","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-g-proteins"},{"source_artifact_id":"wiki-mechanisms-psp-mitochondrial-dysfunction","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-psp-mitochondrial-dysfunction"},{"source_artifact_id":"wiki-mechanisms-cbs-pyroptosis-inflammasome-activation","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 41x in wiki/mechanisms-cbs-pyroptosis-inflammasome-activation"},{"source_artifact_id":"wiki-mechanisms-pkr-pathway-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-pkr-pathway-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-purinergic-signaling","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 8x in wiki/mechanisms-purinergic-signaling"},{"source_artifact_id":"wiki-mechanisms-pink1-parkin-mitophagy-pd-causal-chain","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-pink1-parkin-mitophagy-pd-causal-chain"},{"source_artifact_id":"wiki-mechanisms-neuroinflammation-causal-reactive-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-neuroinflammation-causal-reactive-parkinsons"},{"source_artifact_id":"wiki-mechanisms-autophagy-lysosomal-alzheimers","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 8x in wiki/mechanisms-autophagy-lysosomal-alzheimers"},{"source_artifact_id":"wiki-mechanisms-als-neuroinflammation","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-als-neuroinflammation"},{"source_artifact_id":"wiki-mechanisms-homocysteine-neurotoxicity","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-homocysteine-neurotoxicity"},{"source_artifact_id":"wiki-mechanisms-amyloid-conformational-strains","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-amyloid-conformational-strains"},{"source_artifact_id":"wiki-mechanisms-sex-specific-mechanisms-parkinsons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-sex-specific-mechanisms-parkinsons"},{"source_artifact_id":"wiki-mechanisms-neuronal-death-ad","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 7x in wiki/mechanisms-neuronal-death-ad"},{"source_artifact_id":"wiki-mechanisms-cortisol-tau-pathway","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-cortisol-tau-pathway"},{"source_artifact_id":"wiki-mechanisms-sex-specific-mechanisms-alzheimers","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-sex-specific-mechanisms-alzheimers"},{"source_artifact_id":"wiki-mechanisms-parkinsons-neuroinflammation","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 13x in wiki/mechanisms-parkinsons-neuroinflammation"},{"source_artifact_id":"wiki-mechanisms-mtor-signaling-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-mtor-signaling-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-endocannabinoid-system","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-endocannabinoid-system"},{"source_artifact_id":"wiki-mechanisms-neuroimmune-interface","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 16x in wiki/mechanisms-neuroimmune-interface"},{"source_artifact_id":"wiki-mechanisms-gasotransmitters-neuroprotection","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/mechanisms-gasotransmitters-neuroprotection"},{"source_artifact_id":"wiki-mechanisms-neuroinflammation-hypothesis","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-neuroinflammation-hypothesis"},{"source_artifact_id":"wiki-mechanisms-galectin-3-mechanism-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-galectin-3-mechanism-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-investment-evidence-convergence-analysis","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/mechanisms-investment-evidence-convergence-analysis"},{"source_artifact_id":"wiki-mechanisms-microglial-priming-pathway","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-microglial-priming-pathway"},{"source_artifact_id":"wiki-mechanisms-bbb-neuroimmune-interface-cbs-psp","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 7x in wiki/mechanisms-bbb-neuroimmune-interface-cbs-psp"},{"source_artifact_id":"wiki-mechanisms-ad-pd-shared-pathways","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-ad-pd-shared-pathways"},{"source_artifact_id":"wiki-mechanisms-amyloid-tau-synergistic-interaction-hypothesis","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-amyloid-tau-synergistic-interaction-hypothesis"},{"source_artifact_id":"wiki-mechanisms-glia-neuron-crosstalk-ad","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 13x in wiki/mechanisms-glia-neuron-crosstalk-ad"},{"source_artifact_id":"wiki-mechanisms-short-chain-fatty-acids","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-short-chain-fatty-acids"},{"source_artifact_id":"wiki-mechanisms-viral-post-infectious-als","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-viral-post-infectious-als"},{"source_artifact_id":"wiki-mechanisms-4r-tauopathies-neuroimmune-comparison","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-4r-tauopathies-neuroimmune-comparison"},{"source_artifact_id":"wiki-mechanisms-neuroinflammation-comparison","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 23x in wiki/mechanisms-neuroinflammation-comparison"},{"source_artifact_id":"wiki-mechanisms-neuroinflammation-pathway","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 13x in wiki/mechanisms-neuroinflammation-pathway"},{"source_artifact_id":"wiki-mechanisms-convergent-pathways-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-convergent-pathways-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-amyloid-oligomers-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-amyloid-oligomers-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-dna-sensing-pathways-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 7x in wiki/mechanisms-dna-sensing-pathways-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-microglial-dysfunction-hypothesis","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/mechanisms-microglial-dysfunction-hypothesis"},{"source_artifact_id":"wiki-mechanisms-syk-kinase-microglial-activation-alzheimers","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-syk-kinase-microglial-activation-alzheimers"},{"source_artifact_id":"wiki-mechanisms-rage-signaling-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-rage-signaling-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-pyroptosis-signaling-pathway-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 25x in wiki/mechanisms-pyroptosis-signaling-pathway-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-type-3-diabetes","link_type":"mentions","strength":0.5,"evidence":"Content: P2RX7 mentioned 4x in wiki/mechanisms-type-3-diabetes"},{"source_artifact_id":"wiki-mechanisms-trem2-cytokine-regulation","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/mechanisms-trem2-cytokine-regulation"},{"source_artifact_id":"wiki-mechanisms-target-family-consolidation-analysis","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 10x in wiki/mechanisms-target-family-consolidation-analysis"},{"source_artifact_id":"wiki-mechanisms-ftd-neuroinflammation","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-ftd-neuroinflammation"},{"source_artifact_id":"wiki-mechanisms-fgf13-mtch2-neuroprotection-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-fgf13-mtch2-neuroprotection-parkinsons"},{"source_artifact_id":"wiki-mechanisms-microglia-disease-comparison","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/mechanisms-microglia-disease-comparison"},{"source_artifact_id":"wiki-mechanisms-emerging-therapeutic-directions","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-emerging-therapeutic-directions"},{"source_artifact_id":"wiki-mechanisms-microglial-polarization","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 6x in wiki/mechanisms-microglial-polarization"},{"source_artifact_id":"wiki-mechanisms-cgas-sting-cytosolic-dna-sensing-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 6x in wiki/mechanisms-cgas-sting-cytosolic-dna-sensing-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-protein-oligomerization-toxicity-pathway","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-protein-oligomerization-toxicity-pathway"},{"source_artifact_id":"wiki-mechanisms-trem2-signaling","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-trem2-signaling"},{"source_artifact_id":"wiki-mechanisms-psychobiotic-therapy-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-psychobiotic-therapy-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-neuroinflammation-microglia-pathway","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 7x in wiki/mechanisms-neuroinflammation-microglia-pathway"},{"source_artifact_id":"wiki-mechanisms-mitochondrial-dysfunction-glial-cells","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 13x in wiki/mechanisms-mitochondrial-dysfunction-glial-cells"},{"source_artifact_id":"wiki-mechanisms-cross-disease-shared-pathways-synthesis","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 6x in wiki/mechanisms-cross-disease-shared-pathways-synthesis"},{"source_artifact_id":"wiki-mechanisms-psp-pyroptosis-inflammasome-activation","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 35x in wiki/mechanisms-psp-pyroptosis-inflammasome-activation"},{"source_artifact_id":"wiki-mechanisms-cbs-microglial-neuroimmune-axis","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-cbs-microglial-neuroimmune-axis"},{"source_artifact_id":"wiki-mechanisms-omega-3-fatty-acid-signaling-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-omega-3-fatty-acid-signaling-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-cbs-er-stress","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-cbs-er-stress"},{"source_artifact_id":"wiki-mechanisms-ad-pd-neuroinflammation-comparison-matrix","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 13x in wiki/mechanisms-ad-pd-neuroinflammation-comparison-matrix"},{"source_artifact_id":"wiki-mechanisms-sirtuin-signaling-pathway","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-sirtuin-signaling-pathway"},{"source_artifact_id":"wiki-mechanisms-innate-immune-signaling-ad","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 11x in wiki/mechanisms-innate-immune-signaling-ad"},{"source_artifact_id":"wiki-mechanisms-melatonin-signaling-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-melatonin-signaling-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-neuroinflammation-ad-pathway","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-neuroinflammation-ad-pathway"},{"source_artifact_id":"wiki-mechanisms-cgas-sting-inhibitors-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 6x in wiki/mechanisms-cgas-sting-inhibitors-parkinsons"},{"source_artifact_id":"wiki-mechanisms-neuroinflammation-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 17x in wiki/mechanisms-neuroinflammation-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-innate-immune-response","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 8x in wiki/mechanisms-innate-immune-response"},{"source_artifact_id":"wiki-mechanisms-emerging-therapeutic-directions-2025-2026","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-emerging-therapeutic-directions-2025-2026"},{"source_artifact_id":"wiki-mechanisms-senostatic-therapies-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-senostatic-therapies-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-nf-kappa-b-signaling-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-nf-kappa-b-signaling-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-mlcs-quantification-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-mlcs-quantification-pd"},{"source_artifact_id":"wiki-mechanisms-necroptosis-alzheimers-disease","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-necroptosis-alzheimers-disease"},{"source_artifact_id":"wiki-mechanisms-metaflammation-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 7x in wiki/mechanisms-metaflammation-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-nad-metabolism-pathway-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: CD38 mentioned 3x in wiki/mechanisms-nad-metabolism-pathway-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-tea-polyphenols-neuroprotection","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/mechanisms-tea-polyphenols-neuroprotection"},{"source_artifact_id":"wiki-mechanisms-senescence-therapeutic-targeting","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 6x in wiki/mechanisms-senescence-therapeutic-targeting"},{"source_artifact_id":"wiki-mechanisms-alzheimers-pathogenesis","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-alzheimers-pathogenesis"},{"source_artifact_id":"wiki-mechanisms-fibrinogen-integrin-alpha-synuclein-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-fibrinogen-integrin-alpha-synuclein-pd"},{"source_artifact_id":"wiki-mechanisms-precision-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 8x in wiki/mechanisms-precision-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-microglial-metabolic-reprogramming","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-microglial-metabolic-reprogramming"},{"source_artifact_id":"wiki-mechanisms-hydrogen-sulfide-signaling-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-hydrogen-sulfide-signaling-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-tlr-signaling-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 9x in wiki/mechanisms-tlr-signaling-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-brain-endothelial-cell-dysfunction-pathway","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-brain-endothelial-cell-dysfunction-pathway"},{"source_artifact_id":"wiki-mechanisms-chemokine-signaling-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-chemokine-signaling-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-calcium-dysregulation-comparison","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 8x in wiki/mechanisms-calcium-dysregulation-comparison"},{"source_artifact_id":"wiki-mechanisms-connexin-hemichannel-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: PANX1 mentioned 11x in wiki/mechanisms-connexin-hemichannel-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-gba-parkinson-risk","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/mechanisms-gba-parkinson-risk"},{"source_artifact_id":"wiki-mechanisms-innate-immune-pattern-recognition-4r-tauopathies","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 29x in wiki/mechanisms-innate-immune-pattern-recognition-4r-tauopathies"},{"source_artifact_id":"wiki-mechanisms-stroke-neurodegeneration-pathway","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-stroke-neurodegeneration-pathway"},{"source_artifact_id":"wiki-mechanisms-nad-metabolism-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: CD38 mentioned 26x in wiki/mechanisms-nad-metabolism-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-neuroinflammation-mitochondria-crosstalk","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 33x in wiki/mechanisms-neuroinflammation-mitochondria-crosstalk"},{"source_artifact_id":"wiki-mechanisms-jnk-p38-mapk-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-jnk-p38-mapk-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-anti-amyloid-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-anti-amyloid-therapeutics"},{"source_artifact_id":"wiki-mechanisms-therapeutic-synergy-combination-rankings","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-therapeutic-synergy-combination-rankings"},{"source_artifact_id":"wiki-mechanisms-inflammaging-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 13x in wiki/mechanisms-inflammaging-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-tlr5-microglia-neuroinflammation-hypothesis","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-tlr5-microglia-neuroinflammation-hypothesis"},{"source_artifact_id":"wiki-mechanisms-cross-disease","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-cross-disease"},{"source_artifact_id":"wiki-mechanisms-neuroinflammation-ad-pd-als","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 17x in wiki/mechanisms-neuroinflammation-ad-pd-als"},{"source_artifact_id":"wiki-mechanisms-psp-tau-caspase-cleavage-truncation","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-psp-tau-caspase-cleavage-truncation"},{"source_artifact_id":"wiki-mechanisms-microglial-neuronal-tauopathies","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-microglial-neuronal-tauopathies"},{"source_artifact_id":"wiki-mechanisms-inpp5d-ship1-dysfunction-neuroinflammation-ad-causal-chain","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 7x in wiki/mechanisms-inpp5d-ship1-dysfunction-neuroinflammation-ad-causal-chain"},{"source_artifact_id":"wiki-mechanisms-neuroinflammation-cross-disease","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 22x in wiki/mechanisms-neuroinflammation-cross-disease"},{"source_artifact_id":"wiki-mechanisms-optn-mitophagy-neurodegeneration-causal-chain","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 10x in wiki/mechanisms-optn-mitophagy-neurodegeneration-causal-chain"},{"source_artifact_id":"wiki-mechanisms-nrti-immunomodulation-alzheimers","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 26x in wiki/mechanisms-nrti-immunomodulation-alzheimers"},{"source_artifact_id":"wiki-mechanisms-neuroinflammation-ad-pd","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 12x in wiki/mechanisms-neuroinflammation-ad-pd"},{"source_artifact_id":"wiki-mechanisms-aging-to-ad-switch-trigger","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-aging-to-ad-switch-trigger"},{"source_artifact_id":"wiki-mechanisms-glucocorticoid-signaling-pathway","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-glucocorticoid-signaling-pathway"},{"source_artifact_id":"wiki-mechanisms-nad-signaling-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: CD38 mentioned 18x in wiki/mechanisms-nad-signaling-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-panoptosis-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 17x in wiki/mechanisms-panoptosis-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-cytokine-storm-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 31x in wiki/mechanisms-cytokine-storm-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-neurovascular-gut-brain-axis-neurodegeneration-synthesis","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-neurovascular-gut-brain-axis-neurodegeneration-synthesis"},{"source_artifact_id":"wiki-mechanisms-extracellular-vesicles-parkinsons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-extracellular-vesicles-parkinsons"},{"source_artifact_id":"wiki-mechanisms-pd-neuroinflammation","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 9x in wiki/mechanisms-pd-neuroinflammation"},{"source_artifact_id":"wiki-mechanisms-dashboard","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-dashboard"},{"source_artifact_id":"wiki-mechanisms-neuroinflammation","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 25x in wiki/mechanisms-neuroinflammation"},{"source_artifact_id":"wiki-mechanisms-flavonoids-alpha-synuclein-aggregation","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-flavonoids-alpha-synuclein-aggregation"},{"source_artifact_id":"wiki-mechanisms-syk-microglial-activation-alzheimers","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-syk-microglial-activation-alzheimers"},{"source_artifact_id":"wiki-mechanisms-peripheral-immune-infiltration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-peripheral-immune-infiltration"},{"source_artifact_id":"wiki-mechanisms-gadd45g-pathological-sensor-gliosis","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-gadd45g-pathological-sensor-gliosis"},{"source_artifact_id":"wiki-mechanisms-pd-neuroinflammation-pathway","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 12x in wiki/mechanisms-pd-neuroinflammation-pathway"},{"source_artifact_id":"wiki-mechanisms-parkinsons-disease-mechanisms","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/mechanisms-parkinsons-disease-mechanisms"},{"source_artifact_id":"wiki-mechanisms-network-pharmacology-neurodegeneration-synthesis","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-network-pharmacology-neurodegeneration-synthesis"},{"source_artifact_id":"wiki-mechanisms-sasp-senescence-associated-secretory-phenotype","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-sasp-senescence-associated-secretory-phenotype"},{"source_artifact_id":"wiki-mechanisms-pannexin-p2x7-signaling","link_type":"mentions","strength":0.5,"evidence":"Content: PANX1 mentioned 57x in wiki/mechanisms-pannexin-p2x7-signaling"},{"source_artifact_id":"wiki-mechanisms-gba1-gcase-lysosome-pd-causal-chain","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-gba1-gcase-lysosome-pd-causal-chain"},{"source_artifact_id":"wiki-mechanisms-gsk3-beta","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-gsk3-beta"},{"source_artifact_id":"wiki-mechanisms-cgas-sting-parkinsons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-cgas-sting-parkinsons"},{"source_artifact_id":"wiki-mechanisms-small-molecule-derivatives-neurodegenerative-pathways","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-small-molecule-derivatives-neurodegenerative-pathways"},{"source_artifact_id":"wiki-mechanisms-cryptoxanthin-neuroprotection","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-cryptoxanthin-neuroprotection"},{"source_artifact_id":"wiki-mechanisms-microglial-state-trajectory-ad","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 12x in wiki/mechanisms-microglial-state-trajectory-ad"},{"source_artifact_id":"wiki-mechanisms-glial-neuron-crosstalk-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 9x in wiki/mechanisms-glial-neuron-crosstalk-parkinsons"},{"source_artifact_id":"wiki-mechanisms-aging-vs-neurodegeneration-comparison","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-aging-vs-neurodegeneration-comparison"},{"source_artifact_id":"wiki-mechanisms-integrated-stress-response-ad","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-integrated-stress-response-ad"},{"source_artifact_id":"wiki-mechanisms-microglia-activation","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 8x in wiki/mechanisms-microglia-activation"},{"source_artifact_id":"wiki-mechanisms-calcium-signaling-ad","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/mechanisms-calcium-signaling-ad"},{"source_artifact_id":"wiki-mechanisms-huntingtin-mitochondrial-dysfunction","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-huntingtin-mitochondrial-dysfunction"},{"source_artifact_id":"wiki-mechanisms-autophagy-lysosomal-ad","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-autophagy-lysosomal-ad"},{"source_artifact_id":"wiki-mechanisms-nfkb-signaling","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/mechanisms-nfkb-signaling"},{"source_artifact_id":"wiki-mechanisms-overview","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-overview"},{"source_artifact_id":"wiki-mechanisms-complement-system-pathway","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-complement-system-pathway"},{"source_artifact_id":"wiki-mechanisms-cgas-sting-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-cgas-sting-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-neuroinflammation-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 15x in wiki/mechanisms-neuroinflammation-parkinsons"},{"source_artifact_id":"wiki-mechanisms-sirt1-alzheimer-pathway","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-sirt1-alzheimer-pathway"},{"source_artifact_id":"wiki-mechanisms-mechanism-categories-pathways","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/mechanisms-mechanism-categories-pathways"},{"source_artifact_id":"wiki-mechanisms-trem2","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-trem2"},{"source_artifact_id":"wiki-mechanisms-neuroinflammation-ad","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 16x in wiki/mechanisms-neuroinflammation-ad"},{"source_artifact_id":"wiki-mechanisms-glp-1-signaling-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-glp-1-signaling-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-therapeutic-targetability-rankings","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-therapeutic-targetability-rankings"},{"source_artifact_id":"wiki-mechanisms-alzheimers-neuroinflammation","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 14x in wiki/mechanisms-alzheimers-neuroinflammation"},{"source_artifact_id":"wiki-mechanisms-purinergic-signaling-parkinsons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/mechanisms-purinergic-signaling-parkinsons"},{"source_artifact_id":"wiki-mechanisms-pyroptosis-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 33x in wiki/mechanisms-pyroptosis-neurodegeneration"},{"source_artifact_id":"wiki-technologies-digital-therapeutics-pd","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/technologies-digital-therapeutics-pd"},{"source_artifact_id":"wiki-technologies-digital-biomarkers-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/technologies-digital-biomarkers-pd"},{"source_artifact_id":"wiki-technologies-wearable-sensors-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/technologies-wearable-sensors-pd"},{"source_artifact_id":"wiki-technologies-rna-editing-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/technologies-rna-editing-therapeutics"},{"source_artifact_id":"wiki-technologies-digital-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/technologies-digital-therapeutics"},{"source_artifact_id":"wiki-technologies-ai-movement-analysis-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/technologies-ai-movement-analysis-pd"},{"source_artifact_id":"wiki-biomarkers-interleukin-1-beta-il1b","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 10x in wiki/biomarkers-interleukin-1-beta-il1b"},{"source_artifact_id":"wiki-biomarkers-neuroimmune-psp-biomarkers","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/biomarkers-neuroimmune-psp-biomarkers"},{"source_artifact_id":"wiki-biomarkers-amyloid-beta-40-abeta-40","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/biomarkers-amyloid-beta-40-abeta-40"},{"source_artifact_id":"wiki-biomarkers-interleukin-18-il18","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/biomarkers-interleukin-18-il18"},{"source_artifact_id":"wiki-biomarkers-alpha-synuclein-seed-kinetics-pd","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/biomarkers-alpha-synuclein-seed-kinetics-pd"},{"source_artifact_id":"wiki-events-mds-2026-neuroprotection-neurorestorative-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/events-mds-2026-neuroprotection-neurorestorative-parkinsons"},{"source_artifact_id":"wiki-entities-amyloid-pet","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/entities-amyloid-pet"},{"source_artifact_id":"wiki-entities-xpro1595","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 4x in wiki/entities-xpro1595"},{"source_artifact_id":"wiki-entities-aria-imaging","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/entities-aria-imaging"},{"source_artifact_id":"wiki-gaps-priority-research-areas","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/gaps-priority-research-areas"},{"source_artifact_id":"wiki-companies-ad-rna-therapeutics","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/companies-ad-rna-therapeutics"},{"source_artifact_id":"wiki-experiments-alpha-synuclein-aggregation-triggers-sporadic-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/experiments-alpha-synuclein-aggregation-triggers-sporadic-pd"},{"source_artifact_id":"wiki-experiments-prion-strain-selective-vulnerability","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/experiments-prion-strain-selective-vulnerability"},{"source_artifact_id":"wiki-experiments-glp1-responder-prediction-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/experiments-glp1-responder-prediction-pd"},{"source_artifact_id":"wiki-experiments-alpha-syn-saa-kinetics-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/experiments-alpha-syn-saa-kinetics-pd"},{"source_artifact_id":"wiki-experiments-synaptic-mitochondrial-resilience-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/experiments-synaptic-mitochondrial-resilience-pd"},{"source_artifact_id":"wiki-experiments-alpha-synuclein-spreading-neurodegeneration-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/experiments-alpha-synuclein-spreading-neurodegeneration-pd"},{"source_artifact_id":"wiki-experiments-combination-therapy-sequencing-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/experiments-combination-therapy-sequencing-pd"},{"source_artifact_id":"wiki-experiments-gap-junction-dysfunction-parkinsons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: PANX1 mentioned 2x in wiki/experiments-gap-junction-dysfunction-parkinsons"},{"source_artifact_id":"wiki-experiments-dopaminergic-neuron-selective-vulnerability-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/experiments-dopaminergic-neuron-selective-vulnerability-pd"},{"source_artifact_id":"wiki-experiments-microglial-immune-hd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/experiments-microglial-immune-hd"},{"source_artifact_id":"wiki-organizations-denali-therapeutics","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/organizations-denali-therapeutics"},{"source_artifact_id":"wiki-diseases-alzheimers-genetic-variants","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: P2RX7 mentioned 2x in wiki/diseases-alzheimers-genetic-variants"},{"source_artifact_id":"wiki-diseases-alzheimers-disease","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/diseases-alzheimers-disease"},{"source_artifact_id":"wiki-diseases-corticobasal-syndrome","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/diseases-corticobasal-syndrome"},{"source_artifact_id":"wiki-diseases-atypical-parkinsonism","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 7x in wiki/diseases-atypical-parkinsonism"},{"source_artifact_id":"wiki-diseases-cerebral-amyloid-angiopathy","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/diseases-cerebral-amyloid-angiopathy"},{"source_artifact_id":"wiki-diseases-frontotemporal-dementia","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/diseases-frontotemporal-dementia"},{"source_artifact_id":"wiki-diseases-parkinsons-genetic-variants","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: P2RX7 mentioned 2x in wiki/diseases-parkinsons-genetic-variants"},{"source_artifact_id":"wiki-diseases-investment-landscape-parkinsons","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NLRP3 mentioned 2x in wiki/diseases-investment-landscape-parkinsons"},{"source_artifact_id":"wiki-diseases-autism","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 5x in wiki/diseases-autism"},{"source_artifact_id":"wiki-ai-tool-storm-stanford","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/ai-tool-storm-stanford"},{"source_artifact_id":"wiki-cell-types-neuroinflammation-sensitive-neurons","link_type":"mentions","strength":0.5,"evidence":"Content: NLRP3 mentioned 3x in wiki/cell-types-neuroinflammation-sensitive-neurons"}],"current_artifact_id":"experiment-exp-c98631a3-a95e-4621-a68f-9cf145b22b97","is_canonical":true,"supersede_chain":["experiment-exp-c98631a3-a95e-4621-a68f-9cf145b22b97"]}